Recombinant CD3E (Otelixizumab Biosimilar) antibody
This Humanized Chimeric antibody specifically detects CD3E (Otelixizumab Biosimilar) in ELISA and WB. It exhibits reactivity toward Human.
Catalog No. ABIN7538054
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 8 Business Days
Quick Overview for Recombinant CD3E (Otelixizumab Biosimilar) antibody (ABIN7538054)
Target
CD3E (Otelixizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Chimeric
Conjugate
This CD3E (Otelixizumab Biosimilar) antibody is un-conjugated
Application
ELISA, Western Blotting (WB)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Otelixizumab Biosimilar - Anti-CD3E mAb - Research Grade
-
Characteristics
- Antibody Type: IgG1-lambda
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Purity
- > 85%
-
Isotype
- IgG1 lambda
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- CD3E (Otelixizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Otelixizumab is a recombinant Humanized (from rat) antibody to Human CD3E. Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases.
-
CAS-No
- 881191-44-2
Target
-
You are here:
